Navigation Links
Northern Ireland company makes major breakthrough in cancer treatment
Date:11/8/2011

The findings of Almac scientists' research have been published in the online version of the Journal of Clinical Oncology (JCO) ahead of the print edition of the journal. The JCO is the peer-reviewed publication of the American Society of Clinical Oncology (ASCO), the world's leading professional society representing physicians who treat people with cancer.

Colon cancer is the third most common cancer in the US. Over 100,000 patients are diagnosed each year and around one quarter of these patients are diagnosed with stage 2 of the disease.

Stage 2 colon cancer has a relatively good prognosis with around 80% of patients cured by surgery but the disease will recur in the remaining 20% within five years.

Although the 20% of patients in which the cancer recurs may benefit from chemotherapy there is currently no test which doctors can use to help identify them.

The JCO report gives detail on the development and validation of a prognostic test designed by Almac, ColDX, specifically developed to identify high risk patients who may benefit from additional therapy.

Professor Paul Harkin, President and Managing Director of Almac's Diagnostic business and Professor of Molecular Oncology at Queen's University Belfast said:

"We have used complex technologies designed in Craigavon, Northern Ireland, to examine tumour samples from around the world to identify a genetic signature which tell us the likelihood of stage 2 colon cancer recurring. This technology will make it much more straightforward for doctors to identify high risk patients who may benefit from chemotherapy.

"Our highly novel test represents a significant breakthrough in how colon cancer can be managed. We believe it has the potential to change clinical practice and save the lives of some cancer patients. "Almac is committed to research which improves the health of people around the world and this is just one example of how we are working to achieve that."

Almac scientists including, Professor Richard Kennedy, Dr Max Bylesjo, Dr Peter Kerr, Dr Timothy Davison and Dr Vitali Proutski were involved in the research.

The test was developed using Almac's proprietary discovery technology and using clinical patient samples from around 14 clinical sites across the world including Queen's University Belfast.

Professor Patrick Johnston, Dean, School of Medicine, Dentistry and Biomedical Sciences at Queen's, said:

"We are pleased to have been able to play a role in helping Almac to develop this groundbreaking technology which we hope could save many lives in the future. Both Queen's and Almac are working tirelessly in advancing cancer research and treatments."

Following further external validation and commercialisation the test could be available to UK patients within a couple of years and potentially even sooner in the US.


'/>"/>
Contact: Andrea Clements
andrea.clements@jprni.com
JPR
Source:Eurekalert  

Related medicine news :

1. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
2. Northern Illinois Proton Center on the Verge of Major Medical Breakthrough
3. Greenway Medical Technologies Donates Electronic Health Record, Clinical Research and Revenue Cycle Solutions to Northern Kentucky University
4. Does the weather cause northerners to get more prostate cancer?
5. Lice Control™ Incorporates the Revolutionary LouseBuster™ Device in its Head Lice Removal Arsenal in Northern California
6. PEDEGO ELECTRIC BIKES Partners with Mike's Bikes in Northern California for Bike to Work Week
7. Infant and Young Child Self-Rescue(TM) Swimming Program Coming to Northern Colorado
8. Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways
9. Study focuses on mephedrone use in Northern Ireland post-ban
10. Child soldier trauma in Uganda shares similarities with Northern Ireland
11. John Theurer Cancer Center to host Eighth Annual Northern New Jersey Breast Cancer Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Northern Ireland company makes major breakthrough in cancer treatment
(Date:5/31/2016)... ... 31, 2016 , ... More than 80 representatives of the Hepatitis B ... Cancer Foundation held an event on National Hepatitis Testing Day outside of Philadelphia City ... the leading cause of liver cancer. , Foundation leaders and the citywide coalition they ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... mix of advanced Artificial Intelligence (AI) and the latest in Clinical Patient ... center is integrating predictive analytic outputs directly into the clinical workflow. These insights ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only drive service to the ... whole. On June 2, Northbound CEO Mike Neatherton and COO Paul Alexander will be ... opening plenary on “Leadership: The Journey to Authenticity” with Onsite Workshops CEO Miles Adcock ...
(Date:5/31/2016)... ... 31, 2016 , ... In his latest video, renowned AstroNumerologist ... humans. Using presidential candidate Donald Trump as an example, Kalsi describes the way ... not about adding numbers up,” says Kalsi. “It is about looking at each ...
(Date:5/31/2016)... ... 31, 2016 , ... TeaZa® Energy, LLC announces the launch of ... No Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers ... , The new flavor is best described as a juicy, taste bud takeover. ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
Breaking Medicine Technology: